Jazz Pharma director sells 1,855 shares for taxes
A Jazz Pharmaceuticals director used 1,855 shares to satisfy tax obligations from RSU vesting, not as an open-market sale.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Jazz Pharmaceuticals plc (JAZZ) director Heather Ann McSharry reported two dispositions of Ordinary Shares on August 31, 2026 to cover tax obligations from the vesting of previously granted restricted stock units. A total of 1,855 shares were delivered or withheld for tax payment, and no Rule 10b5-1 plan is reported.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Tax Withholding | Ordinary Shares F1 | 15 | $244.6447 | $4K |
| Tax Withholding | Ordinary Shares F1 | 1,840 | $241.39 | $444K |
Footnotes (1)
- F1. Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units.
Key Figures
Key Terms
restricted stock units financial
tax obligations financial
beneficial ownership financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transactions did JAZZ director Heather Ann McSharry report on August 31, 2026?
Were the August 31, 2026 JAZZ Form 4 transactions open-market sales?
Did the JAZZ Form 4 indicate use of a Rule 10b5-1 trading plan?
What role does Heather Ann McSharry have at Jazz Pharmaceuticals (JAZZ)?
AI-generated analysis. How Rhea-AI works. Not financial advice.